Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling.

Tytuł:
The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling.
Autorzy:
Worth AA; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Shoop R; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Tye K; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Feetham CH; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
D'Agostino G; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.; Rowett Institute, University of Aberdeen, Aberdeen, United Kingdom.
Dodd GT; School of Biomedical Sciences, The University of Melbourne, Victoria, Australia.
Reimann F; Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom.
Gribble FM; Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom.
Beebe EC; Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States.
Dunbar JD; Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States.
Alexander-Chacko JT; Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States.
Sindelar DK; Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States.
Coskun T; Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States.
Emmerson PJ; Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, United States.
Luckman SM; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Źródło:
ELife [Elife] 2020 Jul 29; Vol. 9. Date of Electronic Publication: 2020 Jul 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Cambridge, UK : eLife Sciences Publications, Ltd., 2012-
MeSH Terms:
Signal Transduction*
Anorexia/*genetics
Brain Stem/*physiology
Growth Differentiation Factor 15/*genetics
Neurons/*physiology
Pica/*genetics
Animals ; Cholecystokinin/metabolism ; Growth Differentiation Factor 15/administration & dosage ; Growth Differentiation Factor 15/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Recombinant Proteins/administration & dosage
References:
J Comp Neurol. 1993 Dec 22;338(4):475-90. (PMID: 8132858)
J Neurosci. 2017 Jan 11;37(2):362-370. (PMID: 28077715)
Cell. 2019 Aug 22;178(5):1231-1244.e11. (PMID: 31402172)
J Neuroendocrinol. 1992 Apr;4(2):149-52. (PMID: 21554590)
Front Neuroendocrinol. 1994 Dec;15(4):301-20. (PMID: 7895890)
Nature. 2017 Oct 12;550(7675):255-259. (PMID: 28953886)
PLoS One. 2014 Jun 27;9(6):e100370. (PMID: 24971956)
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9. (PMID: 9326641)
Nat Med. 2007 Nov;13(11):1333-40. (PMID: 17982462)
Neuroscience. 1997 Mar;77(1):23-35. (PMID: 9044371)
Nat Commun. 2016 Jun 15;7:11905. (PMID: 27301688)
Cell Metab. 2018 Sep 4;28(3):353-368. (PMID: 30184485)
Nat Neurosci. 2017 Jul;20(7):934-942. (PMID: 28581479)
PLoS One. 2017 Jan 12;12(1):e0168416. (PMID: 28081177)
Wellcome Open Res. 2018 Sep 21;3:123. (PMID: 30345390)
Clin Chem. 2013 Nov;59(11):1613-20. (PMID: 23873716)
Cell Metab. 2019 Mar 5;29(3):707-718.e8. (PMID: 30639358)
Physiol Behav. 2014 Sep;136:47-54. (PMID: 24508750)
Nat Neurosci. 2000 Jul;3(7):645-6. (PMID: 10862694)
Clin Cancer Res. 2003 Jul;9(7):2642-50. (PMID: 12855642)
J Neurosci. 2015 Aug 5;35(31):11094-104. (PMID: 26245970)
Neurosci Lett. 2004 Apr 8;359(1-2):109-13. (PMID: 15050723)
Nat Med. 2017 Oct;23(10):1215-1219. (PMID: 28846098)
Trends Endocrinol Metab. 2003 Mar;14(2):60-5. (PMID: 12591175)
PLoS One. 2015 Jul 24;10(7):e0133362. (PMID: 26207898)
Endocrinology. 2012 Oct;153(10):4600-7. (PMID: 22869346)
Int J Obes (Lond). 2014 Dec;38(12):1555-64. (PMID: 24531647)
PLoS One. 2013;8(2):e55174. (PMID: 23468844)
Neuron. 2011 Sep 22;71(6):995-1013. (PMID: 21943598)
Diabetologia. 2012 Sep;55(9):2445-55. (PMID: 22638549)
Endocrinology. 1997 Oct;138(10):4445-55. (PMID: 9322962)
Cancer Res. 2006 May 15;66(10):4983-6. (PMID: 16707416)
PLoS One. 2018 Aug 2;13(8):e0201584. (PMID: 30070999)
Neuron. 2018 Nov 21;100(4):891-899.e5. (PMID: 30344042)
Nat Neurosci. 2014 Sep;17(9):1240-8. (PMID: 25064852)
Nat Commun. 2018 Mar 21;9(1):1178. (PMID: 29563502)
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3410-5. (PMID: 12624183)
Nature. 2012 Mar 14;483(7391):594-7. (PMID: 22419158)
PLoS One. 2012;7(4):e34868. (PMID: 22514681)
Elife. 2016 Mar 14;5:. (PMID: 26974347)
Nature. 2013 Nov 7;503(7474):111-4. (PMID: 24121436)
Neuroscience. 2017 Sep 1;358:316-324. (PMID: 28684275)
Cell Metab. 2018 Oct 2;28(4):619-630.e5. (PMID: 30146485)
Sci Transl Med. 2017 Oct 18;9(412):. (PMID: 29046435)
Nat Commun. 2019 Jun 24;10(1):2769. (PMID: 31235690)
Nature. 2020 Feb;578(7795):444-448. (PMID: 31875646)
Nat Med. 2017 Oct;23(10):1150-1157. (PMID: 28846097)
Nat Med. 2017 Oct;23(10):1158-1166. (PMID: 28846099)
Cell Metab. 2014 Oct 7;20(4):639-49. (PMID: 25176149)
Cell Rep. 2020 Apr 21;31(3):107543. (PMID: 32320650)
Mol Metab. 2019 Mar;21:13-21. (PMID: 30685336)
Cell Metab. 2020 Feb 4;31(2):351-362.e5. (PMID: 31928886)
Endocrinology. 2006 Jul;147(7):3190-5. (PMID: 16601142)
Front Endocrinol (Lausanne). 2013 Mar 05;4:20. (PMID: 23467899)
Clin Chem. 2007 Feb;53(2):284-91. (PMID: 17185363)
Eur J Pharmacol. 2014 Oct 5;740:364-78. (PMID: 25058905)
Cancer Res. 2003 Jul 15;63(14):4144-9. (PMID: 12874019)
Grant Information:
MR/R002991/1 United Kingdom MRC_ Medical Research Council; BB/S008098/1 United Kingdom BB_ Biotechnology and Biological Sciences Research Council; MR/P009824/2 United Kingdom MRC_ Medical Research Council; MR/P009824/1 United Kingdom MRC_ Medical Research Council; MR/T032669/1 United Kingdom MRC_ Medical Research Council; MC_UU_12012/5 United Kingdom MRC_ Medical Research Council; MC_UU_12012/3 United Kingdom MRC_ Medical Research Council; MC_UU_00014/3 United Kingdom MRC_ Medical Research Council; BB/M001067/1 United Kingdom BB_ Biotechnology and Biological Sciences Research Council; BB/H007172/1 United Kingdom BB_ Biotechnology and Biological Sciences Research Council; BB/L021129/1 United Kingdom BB_ Biotechnology and Biological Sciences Research Council; MR/L021129/1 United Kingdom MRC_ Medical Research Council
Contributed Indexing:
Keywords: CCK; GDF15; GFRAL; brainstem; cisplatin; food intake; mouse; neuroscience; rat
Substance Nomenclature:
0 (GDF15 protein, human)
0 (Gdf15 protein, mouse)
0 (Growth Differentiation Factor 15)
0 (Recombinant Proteins)
9011-97-6 (Cholecystokinin)
Entry Date(s):
Date Created: 20200730 Date Completed: 20210212 Latest Revision: 20230201
Update Code:
20240104
PubMed Central ID:
PMC7410488
DOI:
10.7554/eLife.55164
PMID:
32723474
Czasopismo naukowe
The cytokine, GDF15, is produced in pathological states which cause cellular stress, including cancer. When over expressed, it causes dramatic weight reduction, suggesting a role in disease-related anorexia. Here, we demonstrate that the GDF15 receptor, GFRAL, is located in a subset of cholecystokinin neurons which span the area postrema and the nucleus of the tractus solitarius of the mouse. GDF15 activates GFRAL AP/NTS neurons and supports conditioned taste and place aversions, while the anorexia it causes can be blocked by a monoclonal antibody directed at GFRAL or by disrupting CCK neuronal signalling. The cancer-therapeutic drug, cisplatin, induces the release of GDF15 and activates GFRAL AP/NTS neurons, as well as causing significant reductions in food intake and body weight in mice. These metabolic effects of cisplatin are abolished by pre-treatment with the GFRAL monoclonal antibody. Our results suggest that GFRAL neutralising antibodies or antagonists may provide a co-treatment opportunity for patients undergoing chemotherapy.
Competing Interests: AW, RS, KT, CF, GD, GD, FR, FG No competing interests declared, EB, JD, JA, DS, TC, PE Paid employee of Eli Lilly. SL BB/S008098/1 is a BBSRC Industrial Partnership Award between SML and Eli Lilly
(© 2020, Worth et al.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies